Atea Pharmaceuticals Inc. (NASDAQ:AVIR) saw a downside of -1.76% to close Friday at $3.34 after subtracting -$0.06 on the day. The 5-day average trading volume is 312,980 shares of the company’s common stock. It has gained $3.46 in the past week and touched a new high 3 times within the past 5 days. An average of 290,840 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 375,782.
AVIR’s 1-month performance is -9.24% or -$0.36 on its low of $3.26 reached on 08/14/23. The company’s shares have touched a 52-week low of $2.94 and high of $8.59, with the stock’s rally to the 52-week high happening on 05/22/23. YTD, AVIR has lost -30.56% or -$1.47 and has reached a new high 4 times. However, the current price is down -61.12% from the 52-week high price.
Insider Transactions
AVIR stock investors last saw insider trading activity on Nov 14.BERGER FRANKLIN M (Director) most recently sold 16,166 shares at $5.16 per share on Nov 14. This transaction cost the insider $83,352. Director, BERGER FRANKLIN M, sold 25,500 shares at a price of $5.15 on Nov 11.
Valuation Metrics
AVIR stock has a beta of 0.16. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.46.
Atea Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 38.40, with the current ratio over the same period at 38.40.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -11.21% to -$28.18 million, while revenue of -$35.47 million was -25.87% off the previous quarter. Analysts expected AVIR to announce -$0.47 per share in earnings in its latest quarter, but it posted -$0.34, representing a 27.70% surprise. EBITDA for the quarter stood at more than -$38.83 million. AVIR stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 23.68 million, with total debt at $2.77 million. Shareholders hold equity totaling $83.4 million.
Let’s look briefly at Atea Pharmaceuticals Inc. (AVIR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 38.66% to suggest the stock is trending Neutral, with historical volatility in this time period at 33.03%.
The stock’s 5-day moving average is $3.37, reflecting a -2.05% or -$0.07 change from its current price. AVIR is currently trading -8.74% above its 20-day SMA, +5.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -26.59% and SMA200 by-44.33%.
Stochastic %K and %D was 28.07% and 28.07% and the average true range (ATR) pointed at 0.14. The RSI (14) points at 39.55%, while the 14-day stochastic is at 21.05% with the period’s ATR at 0.14. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.04 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Atea Pharmaceuticals Inc. (NASDAQ: AVIR), JP Morgan downgraded it to an Underweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for AVIR stock have a consensus rating for the stock as Hold. Currently, 2 brokerage advisors rate AVIR as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is AVIR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $4.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Atea Pharmaceuticals Inc. (AVIR) stock is $4.00.
